Recovering scientist turned early stage VC A biotech optimist fighting gravity

Specialist Fund Flows Help Fuel The Biotech Capital Markets
October 17, 2016

Fund flows between sectors are a critically important dynamic in the equity capital markets: when net fund flows are positive, more demand for equity exists and stock price movement bias upwards; conversely, when fund flows are negative, the selling pressure

Leave a comment

Exploring Company Contributions To The Origination Of New Medicines
October 13, 2016

A new FDA approval marks a major milestone in the biopharmaceutical business; relatively few biopharma companies are ever able to lay claim to having discovered, developed, or marketed a recently approved medicine. As of mid-October, the FDA has approved 17

Leave a comment

Biotech IPOs: Outliers, Value Creation, And The Dispersion Of Returns
September 27, 2016

Although many wrote off the biotech IPO markets as moribund earlier in 2016, the sector has been quietly issuing a steady stream of new offerings. Despite the volatility related to drug pricing, and disastrous first six-weeks of the year, we’ve

1 Comment

Building A Stronger Ecosystem to Combat Antimicrobial Resistance
September 26, 2016

This blog was written by Ankit Mahadevia, CEO of Spero Therapeutics, as part of the From The Trenches feature of LifeSciVC.  Relative to a decade ago, those of us that have spent time finding new ways to outsmart drug-resistant bacteria

Leave a comment

Saluting Biotech M&A: Onward And Upward
September 23, 2016

As larger Pharma externally-enables more of its pipelines, the cadence of biotech M&A appears to be accelerating, especially for early stage deals. Another week, another biotech acquisition in the news: Allergan has acquired two private and two public R&D-stage companies in just

1 Comment

Beyond Biotech M&A: What Comes Thereafter
September 22, 2016

This post was written by Samantha Truex, former CBO of Padlock Therapeutics, as part of the From The Trenches feature of LifeSciVC. Biotech M&A is all the rage these days. Allergan has acquired four small companies in the past couple

Leave a comment

Re-Balancing Immunity via Regulatory T Cell Potentiation: Introducing Delinia
September 20, 2016

This blog is written by Michael Gladstone, Principal at Atlas, as part of the From The Trenches feature of LifeSciVC. Charles de Gaulle once asked, “How can you govern a country which has 246 varieties of cheese?” But that might seem

1 Comment

Potential Silver Lining Of Pharma Price Pressure: More Biotech Deal-making?
September 14, 2016

The maelstrom around drug pricing has continued its fury over the past month, which has led to considerable volatility in the biopharma stock market. Investor fears of draconian price controls that will eliminate the return of investment from innovative pharmaceutical


Innovators vs Exploiters: Drug Pricing And The Future Of Pharma
August 29, 2016

Pharmaceutical pricing got thrown onto the front page again last week, causing the expected anaphylactic reactions among politicians, practitioners, and parents. The root of this crisis: Epipen’s 600% price increase over the past eight years. The biannual upticks underlying that


Setting Up A US Biotech Subsidiary: Cambridge, Old England To Cambridge, New England
August 23, 2016

This post was written by Ros Deegan, CBO of Bicycle Therapeutics, as part of the From The Trenches feature of LifeSciVC. Sail-away It’s January on a ship in the South Pacific. Instead of enjoying hula and coconuts, I’m struggling to

Leave a comment

Digital Health: The Convergence Of Consumer Devices And Clinical Applications
August 19, 2016

This post was written by Adam Rosenberg, CEO of Rodin Therapeutics, as part of the From The Trenches feature of LifeSciVC. Those of us in biotech tend to focus our attention on drug discovery and development, but it is also

1 Comment

Birth: An Epic Day Of Bacterial Invasion
August 18, 2016

This post was written by JC Gutierrez-Ramos, CEO of Synlogic, as part of the From The Trenches feature of LifeSciVC. When I was a graduate student, I listened to the famous developmental biologist Lewis Wolpert say, “It is not birth